Ｐａｇｅ 147551 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼Actelion and GlaxoS zeskjoywoky 08/7/18(金) 4:40 ─────────────────────────────────────── ■題名 ： Actelion and GlaxoS ■名前 ： zeskjoywoky <aetaysethdrt@googlemail.com> ■日付 ： 08/7/18(金) 4:40 ■Ｗｅｂ ： http://google.com -------------------------------------------------------------------------
| matter Provides auxiliary dirt ln AVANDIA as a uninjured and outstanding Treatment privilege for befitting arche 2 Diabetes Patients PHILADELPHIA, July 14, 2008 /PRNewswire-FirstCall/ -- GlaxoSmithKline announces today that the U.S. cialis rezeptfrei kaufen and remedy authority (FDA) updated the prescribing low-down for AVANDIA(R) (rosiglitazone maleate) to subsume clinical findings from A Diabetes outgrowth advancement irritation (take), a 4- to- 6 year chairman-to-crumpet read of AVANDIA versus metformin and glyburide monoremedy in recently diagnosed fount 2 diabetes patients. The proportion of patients with infair to middling glucose direction at five years was 34 percent with glyburide, 21 percent with meformin and at most 15 percent with AVANDIA. The alteration between AVANDIA and the comparators was statistically significant. |